Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies.

Q1 Medicine Current Gastroenterology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI:10.1007/s11894-024-00920-0

Alireza Tojjari, Robin Park, James Yu, Anwaar Saeed

{"title":"Targeting Angiogenesis Alone and in Combination with Immune Checkpoint Inhibitors in Advanced Gastroesophageal Malignancies.","authors":"Alireza Tojjari, Robin Park, James Yu, Anwaar Saeed","doi":"10.1007/s11894-024-00920-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review critically examines the latest approaches in treating advanced gastroesophageal malignancies. It emphasizes the significance of angiogenesis as a therapeutic target and discusses the potential synergy of combining angiogenesis inhibitors with immune checkpoint inhibitors (ICIs) to enhance treatment efficacy.Recent findings: Emerging evidence from clinical trials, such as the INTEGRATE IIa trial with regorafenib and studies involving apatinib and sunitinib, underscores the efficacy of targeting the VEGFR pathway. These studies indicate substantial benefits in progression-free survival (PFS) and overall survival (OS) in patients with advanced stages of the disease who have limited treatment options. Additionally, the recent introduction of combination therapies involving ICIs has shown an increased response rate, suggesting a promising direction for future treatment protocols. The landscape of treatment for gastroesophageal malignancies is rapidly evolving. Research is now pivoting from conventional chemotherapy to a more nuanced approach that includes targeted therapy and immunotherapy.","PeriodicalId":10776,"journal":{"name":"Current Gastroenterology Reports","volume":" ","pages":"57-67"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Gastroenterology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11894-024-00920-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review critically examines the latest approaches in treating advanced gastroesophageal malignancies. It emphasizes the significance of angiogenesis as a therapeutic target and discusses the potential synergy of combining angiogenesis inhibitors with immune checkpoint inhibitors (ICIs) to enhance treatment efficacy.

Recent findings: Emerging evidence from clinical trials, such as the INTEGRATE IIa trial with regorafenib and studies involving apatinib and sunitinib, underscores the efficacy of targeting the VEGFR pathway. These studies indicate substantial benefits in progression-free survival (PFS) and overall survival (OS) in patients with advanced stages of the disease who have limited treatment options. Additionally, the recent introduction of combination therapies involving ICIs has shown an increased response rate, suggesting a promising direction for future treatment protocols. The landscape of treatment for gastroesophageal malignancies is rapidly evolving. Research is now pivoting from conventional chemotherapy to a more nuanced approach that includes targeted therapy and immunotherapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在晚期胃食管恶性肿瘤中单独或与免疫检查点抑制剂联合靶向血管生成

综述的目的：这篇综述认真研究了治疗晚期胃食管恶性肿瘤的最新方法。它强调了血管生成作为治疗靶点的重要性，并讨论了将血管生成抑制剂与免疫检查点抑制剂（ICIs）相结合以提高疗效的潜在协同作用：来自临床试验的新证据，如使用瑞戈非尼的 INTEGRATE IIa 试验以及涉及阿帕替尼和舒尼替尼的研究，都强调了靶向血管内皮生长因子受体途径的疗效。这些研究表明，对于治疗方案有限的晚期患者来说，无进展生存期（PFS）和总生存期（OS）都有很大益处。此外，最近推出的 ICIs 联合疗法也显示出更高的反应率，为未来的治疗方案指明了方向。胃食管恶性肿瘤的治疗格局正在迅速演变。目前的研究正从传统化疗转向包括靶向治疗和免疫治疗在内的更细致的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Gastroenterology Reports Medicine-Gastroenterology

CiteScore

7.80

自引率

0.00%

发文量

期刊介绍： As the field of gastroenterology and hepatology rapidly evolves, the wealth of published literature can be overwhelming. The aim of the journal is to help readers stay abreast of such advances by offering authoritative, systematic reviews by leading experts. We accomplish this aim by appointing Section Editors who invite international experts to contribute review articles that highlight recent developments and important papers published in the past year. Major topics in gastroenterology are covered, including pediatric gastroenterology, neuromuscular disorders, infections, nutrition, and inflammatory bowel disease. These reviews provide clear, insightful summaries of expert perspectives relevant to clinical practice. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.

期刊最新文献

Gastric Per-Oral Endoscopy Myotomy (G-POEM): Tips, Tricks, and Pitfalls. The Current Landscape of Endoscopic Submucosal Training in the United States. Endoscopic Gallbladder Drainage EUS LAMS vs. ERCP Trans-papillary Drainage. Yoga in Pediatric Gastroenterology. Perspectives and Advice from an Interventional Gastroenterologist at a Tertiary Academic Center.